Comparative Pharmacology
Head-to-head clinical analysis: ERGOLOID MESYLATES versus MIGRANAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERGOLOID MESYLATES versus MIGRANAL.
ERGOLOID MESYLATES vs MIGRANAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.
MIGRANAL (dihydroergotamine mesylate) is an ergot alkaloid with agonist activity at serotonin 5-HT1D and 5-HT1B receptors, leading to vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission, thereby aborting migraine attacks.
Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.
1 mg intramuscularly at onset of migraine headache; may repeat after 1 hour if needed. Maximum: 2 mg per day and 4 mg per week.
None Documented
None Documented
2-4 hours for parent drug; clinical significance: drug accumulation unlikely with normal dosing intervals.
Terminal elimination half-life ranges from 7 to 10 hours (mean 8.5 hours). Prolonged in renal impairment.
Primarily fecal (biliary) as metabolites and unchanged drug; renal elimination accounts for less than 10% of the dose.
Primarily hepatic metabolism followed by renal excretion. Approximately 10% excreted unchanged in urine; fecal excretion accounts for <1%.
Category A/B
Category C
Ergot Alkaloid
Ergot Alkaloid